Industry & Business

156K cancer patients could miss out on life-saving drugs every year in US and Europe

 Breaking News
  • Microsoft’s New Irish Wind Energy Agreement The national body charged with helping Ireland to transition to a low-carbon economy has welcomed a new agreement by Microsoft to become one of the first multinational technology companies to support a new wind project in Ireland. Microsoft Corp. has announced a 15-year power purchase agreement (PPA) with GE to purchase 100 percent of the [...]...
  • Review of Energy Supplier Costs The Commission for Regulation of Utilities (CRU) has published its analysis on supplier costs in the electricity and gas retail markets in Ireland. This follows the review of how the energy retail market competition has evolved following full price deregulation of electricity and gas retail tariffs that was published in February 2017. CRU reviews the retail [...]...
  • Combilift Signs $1 Million Contract in Australia Combilift, the Irish manufacturer of multi-directional forklifts based in Monaghan, has signed a contract with Civmec, an Australian construction and engineering company that is worth an additional $1 million to the Irish company. Civmec is an integrated, multi-disciplined construction and engineering services provider to the oil and gas, metals and minerals, infrastructure and defence markets [...]...
  • Irish Women More Likely to Have a Third-level Qualification Than Men The Central Statistics Office has published ‘Women and Men in Ireland 2016′ which presents over 70 indicators that identify important gender differences in the activities of men and women and also presents the situation in Ireland in an international context. Statistician Helen Cahill comments: “More girls than boys sat higher level papers in the Leaving Certificate [...]...
  • The Future is FeMale An international study of global attitudes towards gender biases and roles has revealed that almost half of both men and women believe the world would be a better place if more women held positions of power. However, the study, carried out by Havas Creative in partnership with Market Probe International, revealed that globally, only 24% [...]...

156K cancer patients could miss out on life-saving drugs every year in US and Europe

156K cancer patients could miss out on life-saving drugs every year in US and Europe
May 19
09:00 2017

Irish medtech company Diaceutics has announced research results showing that more than 156,000 cancer patients in the US and Europe could be missing out on targeted life-saving drugs every year due to suboptimal diagnostic testing – therefore potentially affecting their chances of survival. The company has also found that substandard testing practices are causing pharmaceutical companies in the US and Europe to miss out on up to €15 billion in potential revenues annually.

Every year, 1.7 million cancer patients in the US and Europe undergo tests that determine whether or not there are precision drugs available that are likely to work better with their genetic makeup than more widely prescribed drugs. However, suboptimal testing practices – such as delayed reporting of test results, false negatives and sample management issue – mean that patients and pharmaceutical companies are missing out.

Diaceutics estimates that the figures are in fact much higher, as its data doesn’t take into account the number of patients that aren’t tested at all. The company’s research has found that even some four years after new diagnostic tests become available, just 50% of patients that may be eligible for precision drugs will have been tested by their physician. That, along with suboptimal testing practices, could be causing pharmaceutical companies to be missing out on up to €50 billion annually.

By providing pharmaceutical companies with valuable insights driven by patient testing data, Diaceutics helps them to reach more patients that need to be on specific – and often life-saving – drugs and roll out those drugs faster. The company’s data is gathered through partnerships with more than 230 laboratories that process diagnostic tests. Through its work, Diaceutics has so far helped with the planning and or launch of more than 200 drugs worldwide.

Peter Keeling, CEO, Diaceutics, said: “Precision medicine is already making a huge impact on people’s lives. However, due to questionable diagnostic test practices, patients are missing out on live-saving drugs, while pharmaceutical companies are missing out on the opportunity to reach those patients. Our real-world, real-time research is showing the gaps that exist today.

“Many of the oncology patients that are tested for precision drugs are seriously ill. Physicians therefore need to be able to see the results of those tests as soon as possible. However, novel tests often suffer from issues with sample management, high rates of false negatives and delayed turnaround times, which lead to patients missing out on the drugs they need and therefore potentially facing a much bleaker prognosis.

“Diaceutics is working to change this by bridging the gap between pharmaceutical companies and diagnostics. We work with hundreds of lab partners across the world, gathering and analysing their patient testing data so that we can better understand testing practices. Labs are often severely constrained by ever-reducing reimbursement, yet our demands on them are increasing. Along with our pharma clients, we are working directly with labs to optimise testing. Our data and analytical insights also help pharmaceutical companies understand testing patterns and more effectively integrate proper diagnostic testing into patients’ treatment journeys.

“Medicine is going to become increasingly reliant on diagnostics in the future. In the next 48 months, some 300 new test-dependent drugs or indications will be brought to market. We therefore need to make sure that labs, pathologists, physicians and pharmaceutical companies are perfectly aligned to prepare for this change and ensure patients are receiving the targeted drugs that have the potential to save their lives.”

About Author

editor

editor

Related Articles






New Subscriber





Subscribe Here



Advertisements
































National Manufacturing Conference & Exhibition 2016

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4